Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy

Atypical hemolytic uremic syndrome (aHUS) is caused by dysregulation of the complement system. A humanised anti-C5 monoclonal antibody (eculizumab) is available for the treatment of aHUS. We present the first description of atypical HUS in a child with a coexistent diagnosis of a POL-III leukodystro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Case Rep Nephrol
Main Authors: Teoh, Chia Wei, Gorman, Kathleen Mary, Lynch, Bryan, Goodship, Timothy H. J., Dolan, Niamh Marie, Waldron, Mary, Riordan, Michael, Awan, Atif
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi 2018
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5818949/
https://ncbi.nlm.nih.gov/pubmed/29552364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2018/2781789
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados